by Admin | Apr 9, 2024 | Portfolio News
SAN DIEGO, CA & SHANGHAI, April 1st, 2024 – Sirius Therapeutics today announced it has dosed the first subject in a Chinese Phase 1 trial of SRSD107, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and...
by Admin | Apr 9, 2024 | Portfolio News
SAN DIEGO, April 8, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has...
by Admin | Mar 27, 2024 | Portfolio News
Financing includes nine new investors and was led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital Proceeds to support advancing AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor SAN...
by Admin | Feb 28, 2024 | Portfolio News
–Company Receives Five-year Exclusivity Extension Through GAIN Act — SAINT-LOUIS, France & WEILL AM RHEIN, Germany, February 27,2024 – Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic...
by Admin | Nov 9, 2023 | Portfolio News
Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive...
by Admin | Oct 19, 2023 | Portfolio News
PT886 is Phanes’ first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck’s anti-PD-1The clinical trial collaboration will focus on evaluating PT886 in combination with KEYTRUDA® for the treatment of claudin 18.2...
by Admin | Oct 19, 2023 | Portfolio News
October 9, 2023, San Diego and Shanghai – Sirius Therapeutics today announced that it has completed a US$60 million Series B financing to advance the clinical development of the Company’s novel siRNA therapeutics and the continued innovation of the...
by Admin | Sep 8, 2023 | Portfolio News
Secured financing advances Instylla’s clinical trials and commercialization readiness BEDFORD, Mass., Aug. 15, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy,...
by Admin | Sep 8, 2023 | Portfolio News
Proceeds to accelerate commercialization and pipeline expansion of novel FLASH™ Aorto-Ostial Angioplasty System CAMPBELL, Calif., Feb. 8, 2023 /PRNewswire/ — Ostial Corporation (Ostial), a private medical technology company focused on...
by Admin | Jun 12, 2023 | Portfolio News
– Proceeds to support the development of Eccogene’s clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders Boston/Shanghai/June 12nd,...
